Pharmaceutical research firm Tonix Pharmaceuticals has unveiled promising preclinical data for its single-dose mpox vaccine candidate, TNX-801, at the World Vaccine Congress Washington 2025. The oral presentation highlighted significant developments in vaccine technology that could potentially address global public health challenges related to mpox outbreaks.
The research demonstrates TNX-801's remarkable efficacy in protecting animal subjects, including those with compromised immune systems, against both mpox and rabbitpox. Notably, the vaccine provided durable protection lasting six months, a critical advancement in vaccine development for infectious diseases.
TNX-801 is designed as a minimally replicative live-virus vaccine, strategically aligned with the World Health Organization's preferred target profile for mpox vaccines. This alignment suggests potential broad applicability in current and future mpox outbreak scenarios that have been designated as global health emergencies.
The vaccine's development represents a significant stride in infectious disease prevention, particularly for populations most vulnerable to mpox transmission. By demonstrating effectiveness across diverse animal models, including immunocompromised subjects, TNX-801 offers hope for a comprehensive vaccination strategy.
The research comes at a critical time when public health officials continue to monitor mpox transmission globally. A single-dose vaccine with extended protection could dramatically simplify vaccination protocols and improve overall pandemic response capabilities.
Tonix Pharmaceuticals' commitment to addressing public health challenges is further underscored by its advanced infectious disease research facility in Frederick, Maryland. The company's purpose-built manufacturing facility in Dartmouth, Maryland, stands ready to rapidly produce the vaccine if national or international emergency requirements emerge.
While further clinical trials and regulatory approvals remain necessary, the preclinical data presented represents a promising step toward developing an effective, long-lasting mpox vaccine. The potential to protect immunocompromised populations, coupled with the vaccine's single-dose format, could significantly impact global infectious disease prevention strategies.
